Small-cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer for which there is no effective treatment 1, 2 . Using a mouse model in which deletion of Rb1 and Trp53 in the lung epithelium of adult mice induces SCLC 3, 4 , we found that the Hedgehog signaling pathway is activated in SCLC cells independently of the lung microenvironment. Constitutive activation of the Hedgehog signaling molecule Smoothened (Smo) promoted the clonogenicity of human SCLC in vitro and the initiation and progression of mouse SCLC in vivo. Reciprocally, deletion of Smo in Rb1 and Trp53-mutant lung epithelial cells strongly suppressed SCLC initiation and progression in mice. Furthermore, pharmacological blockade of Hedgehog signaling inhibited the growth of mouse and human SCLC, most notably following chemotherapy. These findings show a crucial cell-intrinsic role for Hedgehog signaling in the development and maintenance of SCLC and identify Hedgehog pathway inhibition as a therapeutic strategy to slow the progression of disease and delay cancer recurrence in individuals with SCLC.
Activation of Hedgehog signaling has been reported in a subset of human SCLC cell lines and tumors [5] [6] [7] [8] without changes in Hedgehog pathway gene copy numbers 9 . Furthermore, we sequenced exons from 16 Hedgehog pathway genes in human SCLC and found no evidence for recurrent mutations (Supplementary Table 1 ). These observations raised questions about the potential roles of Hedgehog signaling in SCLC development as well as the relative contributions of cell-autonomous and non-cell-autonomous Hedgehog activity 10 . To investigate the Hedgehog pathway in SCLC in vivo, we first crossed mice carrying conditional alleles of Rb1 and Trp53 to Ptch1 lacZ/+ (Ptch1 is also known as Ptc1) mice in which LacZ activity parallels Hedgehog pathway activation 11 . X-gal staining revealed that the vast majority of mouse SCLC (mSCLC) stained positive for lacZ activity in vivo 9-12 months after exposure to adenovirus expressing Cre (Ad-Cre) (Fig. 1a) . The X-gal staining intensity was similar to that found in the cerebellum of Ptch1 lacZ/+ mice ( Supplementary Fig. 1a,b) . We found no recurrent copy number changes in Hedgehog pathway genes in mouse tumors (Supplementary Table 2 ), which argues against mutations directly activating Hedgehog signaling in this model. Non-SCLC mouse lung tumors induced by oncogenic Kras 12 were largely negative for LacZ activity (Supplementary Fig. 1c,d) . A subset of stromal cells underlying the bronchiolar epithelium also stained positive for X-gal, both in wild-type and Rb1-and Trp53-mutant mice, indicating that this result was not caused by tumor-suppressor loss (Fig. 1a,  Supplementary Fig. 2 and data not shown). We found reporter activity in ~60% of the small lesions and weak X-gal staining in ~35-40% of neuroendocrine cells, which are considered candidates for the cell of origin of SCLC 13, 14 (Fig. 1b and Supplementary Fig. 2a,b) . Otherwise, only subsets of tracheal epithelial cells stained positive for LacZ activity (Supplementary Fig. 2c ).
Rb1-Trp53-Ptch1 lacZ/+ tumor cells expressed lacZ in culture (Fig. 1c ) and in allografts (Fig. 1c) , and seven of eight single-cell subclonal cultures derived from Rb1-Trp53-Ptch1 lacZ/+ tumors retained LacZ activity (Fig. 1c and data not shown) . These subclones expressed components of the Hedgehog pathway (Fig. 1d and Supplementary  Fig. 3a,b) . Thus, Rb1-Trp53 mutant mSCLC cells maintain Hedgehog activity cell autonomously and independently of the lung cellular microenvironment. Shh-LIGHT2 reporter cells, in which the luciferase reporter is induced when the Hedgehog pathway is active 15 , were A crucial requirement for Hedgehog signaling in small cell lung cancer cultured with conditioned medium from mSCLC cells but showed no induction of reporter activity (data not shown). However, culture of the reporter cells with the mSCLC cells resulted in mild luciferase induction (Fig. 1e) , suggesting active Hedgehog ligands that may be retained in close proximity to the producing cells. Accordingly, immunohistochemistry analysis showed that mSCLC cells expressed Hedgehog ligands in vivo (Fig. 1f) . Appropriate Hedgehog signaling depends on a functional primary cilium 16, 17 . We found that ~12% of mSCLC spheres in culture and subsets of neuroendocrine tumor cells in vivo (Fig. 1f) had a primary cilium. Moreover, addition of conditioned medium containing active Sonic hedgehog to mSCLC cells grown in low serum enhanced their survival and increased expression of the Hedgehog pathway member and target Gli1 (Fig. 2a,b) . Together, these data suggest that the Hedgehog pathway is active in mSCLC cells through an autocrine-juxtacrine loop and that one function of the pathway is to enhance survival.
We next crossed Rb1-Trp53 conditional mutant mice to Rosa26 +/LSL-SmoM2−YFP (Rosa26 is also known as Gt(ROSA)26Sor) mice carrying a conditional, constitutively active mutant allele of Smo (SmoM2) fused to YFP (also known as Tg(Thy1-YFP)16Jrs) 18 ( Fig. 2c) . We aged cohorts of Ad-Cre-infected Rb1 lox/lox ; Trp53 lox/lox ; Rosa26 +/LSL-SmoM2-YFP (Rb1-Trp53-SmoM2) and Rb1 lox/lox ; Trp53 lox/lox (Rb1-Trp53) mice for 8 months. All Rb1-Trp53-SmoM2 tumors analyzed expressed YFP, and analysis of Gli1 mRNA levels was indicative of a physiological activation of the Hedgehog pathway in these tumors (Supplementary Fig. 4 ). Rb1-Trp53-SmoM2 mice developed more mSCLCs than did their Rb1-Trp53 littermates (these mSCLCs were also associated with a greater tumor volume and higher mitotic index) but had comparable apoptotic cell death levels ( Fig. 2d-f and Supplementary Fig. 5 ). We also determined that Hedgehog pathway activation could not replace loss of Rb1 or Trp53 using Rb1 +/lox ; Trp53 lox/lox ; Rosa26 +/LSL-SmoM2-YFP or Rb1 lox/lox ; Trp53 +/lox ; Rosa26 +/LSL-SmoM-YFP mice because one wild-type Trp53 allele was sufficient to prevent tumor development for up to 8-9 months after Ad-Cre exposure (data not shown), whereas retention of a wild-type Rb1 allele produced features of lung adenocarcinoma but not SCLC ( Supplementary Fig. 6 and data not shown). The inability of SmoM2 alone to initiate tumors in lung epithelium may be because of its weak activity and/or the ability of Trp53 to normally restrict full Hedgehog signaling activation 19 .
In determining whether Hedgehog signaling was required for the expansion of SCLC tumor cells, we found that treatment with cyclopamine, a Smo inhibitor 20 , decreased the survival of SCLC cells in low serum and also decreased Gli1 mRNA levels; a structural analog of cyclopamine, tomatidine, which does not inhibit Smo function, had minimal effects ( Supplementary Fig. 7a,b) . To rule out nonspecific activities of cyclopamine 10 , we treated mSCLC cell lines with HPI-1 (ref. 21 ) and GANT-61 (ref. 22) , two inhibitors of Gli proteins; this treatment reduced Gli1 levels and cell survival compared to vehicle treatment (Fig. 3a,b and Supplementary Fig. 7c,d ). We observed similar effects with the Smo inhibitor NVP-LDE225 (refs. 23,24) (Supplementary Fig. 7e ). We observed decreased proliferation and increased apoptosis in mSCLC tumors that we treated short term with cyclopamine in vivo (Fig. 3c,d and Supplementary Fig. 7f) ; these levels were comparable to those seen with cisplatin, a platinum-based drug used to treat individuals with SCLC 2 (Fig. 3d) . Staining for the (Fig. 3e) . Rb1-Trp53-Rbl2 tripleknockout mice with mutated Smo developed fewer and smaller tumors than did their littermates that had wild-type Smo and those that were heterozygous for Smo (Fig. 3f-h and data not shown). Histopathological analysis confirmed that all tumors had features of SCLC (Fig. 3g and data not shown) . This decrease in tumor number was associated with a lower mitotic index but not with a change in cell death levels at this time point (Fig. 3i) . Thus, the Hedgehog pathway contributes to the maintenance of mSCLC tumors and participates in their initial development in vivo.
A major issue in the management of individuals with SCLC is disease recurrence following chemotherapy. We tested the possibility that signaling downstream of Smo has a role in this process by manipulating the activity of the Hedgehog pathway in suspension cultures of human LX22CL cells (derived from the primary xenograft line LX22) 25 . Inhibition of Hedgehog signaling resulted in fewer colonies, whereas activation of Smo signaling increased the cells' long-term ability to grow in a clonogenic assay 26 (Fig. 4a) . LX22CL cells surviving a single carboplatin and etoposide treatment showed an increased sensitivity to manipulation of ligand-dependent Smo signaling in the same assay (Fig. 4a) .
In contrast to what we observed with mSCLC cells, only a small fraction of human chemonaive SCLC cells (<1%) expressed a primary cilium (data not shown). However, three rounds of treatment with carboplatin and etoposide produced a strong increase in the number of LX22CL cells with a primary cilium (~20%). We were able to modify Smo localization in the primary cilia of these cells by manipulating the Hedgehog pathway (Fig. 4b,c) . Furthermore, LX22 primary SCLC xenografts had a marked increase in the expression of Sonic hedgehog and nuclear Gli2 following chemotherapy ( Supplementary Fig. 8a,b) . Although we did not detect cilia in chemonaive xenografts (data not shown), approximately 10% of chemoresistant LX22 tumor cells had primary cilia (Supplementary Fig. 8c) . Thus, the increased sensitivity of chemoresistant SCLC cells to the inhibition of Smo signaling is directly correlated with Smo localization in the primary cilia of these cells, which is a sign of activation of the Hedgehog pathway.
To test the idea that chemotherapy and Smo inhibition might cooperate, we treated mice bearing LX22 xenografts with carboplatin and etoposide chemotherapy followed by oral administration of NVP-LDE225. NVP-LDE225 monotherapy in chemonaive tumors had little effect on tumor growth. Notably, however, NVP-LDE225 treatment was highly effective in preventing the recurrence of residual tumors following chemotherapy (Fig. 4d) . The histopathology of these xenografts following treatment was unchanged (Supplementary Fig. 8d) .
Direct mutations affecting key regulators of the Hedgehog signaling pathway are potent drivers of tumors 8, 27 that are sensitive to pharmacological inhibition of the Hedgehog pathway 28, 29 . SCLC cells do not carry recurrent mutations in Hedgehog pathway genes but are nevertheless sensitive to Hedgehog pathway inhibition, largely in a cell-autonomous manner. Such a mode of action for Hedgehog signaling may be relevant to several cancer types [30] [31] [32] [33] [34] [35] [36] [37] (Supplementary Discussion). Our study also reveals a previously unsuspected role for the Hedgehog pathway during SCLC initiation in addition to its role in the maintenance of tumors, suggesting that both early and advanced SCLC lesions may be responsive to Hedgehog pathway inhibitors. Future experiments should investigate the exact mode of action of Hedgehog molecules on SCLC cells, including juxtacrine and autocrine mechanisms. The cell-intrinsic activation of Hedgehog signaling in SCLC raises the possibility that metastasis of SCLC cells is largely independent of their microenvironment 34 . Finally, our data indicate that treatment of individuals with SCLC with Hedgehog pathway inhibitors may cooperate with chemotherapy and/or radiation therapy regimens to inhibit the growth of primary and metastatic SCLC and to reduce tumor recurrence in affected individuals.
MeTHodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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